For the quarter ending 2026-03-31, PTHS made $10,906,000 in revenue. -$7,049,000 in net income. Net profit margin of -64.63%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenue | 10,906,000 | -5,423,000* | 7,406,000 | - |
| Cost of goods sold | 1,673,000 | -2,960,000* | 2,316,000 | - |
| Selling, general and administrative | 21,104,000 | 2,321,086.5* | 19,628,000 | - |
| Research and development | 186,000 | 238,279* | 145,000 | 514,814 |
| Professional fees | - | - | - | 1,605,525 |
| General and administrative expenses | - | - | - | 1,110,084 |
| Amortization of intangible assets | 1,031,000 | -481,000* | 679,000 | - |
| Total operating expenses | 23,994,000 | -881,634.5* | 22,768,000 | 3,230,423 |
| Operating loss | -13,088,000 | -4,541,365.5* | -15,362,000 | -3,230,423 |
| Interest expense | 2,353,000 | -1,026,000* | 1,346,000 | - |
| Impairment of intangible assets | - | 71,250* | - | - |
| Interest income and other income | - | - | 5,000 | 0 |
| Change in fair value of convertible debt | 5,203,000 | -16,892,726* | - | - |
| Interest expense | - | - | - | 218,516 |
| Interest income and other income | - | 1,250* | - | - |
| Total other (expense) income | 2,850,000 | -15,936,726* | -1,341,000 | -218,516 |
| Net loss before provision for income taxes | -10,238,000 | -20,478,091.5* | -16,703,000 | -3,448,939 |
| Provision for income taxes | 0 | -6,689,500* | -465,000 | 0 |
| Net loss | -10,238,000 | -13,788,591.5 | - | -3,448,939 |
| Change in fair value of convertible debt due to instrument credit risk | 3,189,000 | - | - | - |
| Net loss and comprehensive loss | - | - | -16,238,000 | - |
| Comprehensive loss | -7,049,000 | - | - | - |
| Basic EPS | -3.09 | -7.332 | -5.3 | -5.38 |
| Diluted EPS | -3.09 | -7.332 | -5.3 | -5.38 |
| Basic Average Shares | 3,311,742 | 1,880,498* | 3,061,488 | 640,518 |
| Diluted Average Shares | 3,311,742 | 1,880,498* | 3,061,488 | 640,518 |
Pelthos Therapeutics Inc. (PTHS)
Pelthos Therapeutics Inc. (PTHS)